First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study
Sullivan, Ryan J, Infante, Jeffrey R, Janku, Filip, Wong, Deborah Jean Lee, Sosman, Jeffrey A, Keedy, Vicki, Patel, Manish R, Shapiro, Geoffrey I, Mier, James W, Tolcher, Anthony W, Wang-Gillam, Andrea, Sznol, Mario, Flaherty, Keith, Buchbinder, Elizabeth, Carvajal, Richard D, Varghese, Anna M, Lacouture, Mario E, Ribas, Antoni, Patel, Sapna P, DeCrescenzo, Gary A, Emery, Caroline M, Groover, Anna L, Saha, Saurabh, Varterasian, Mary, Welsch, Dean J, Hyman, David M, Li, Bob T
Published in Cancer discovery (01.02.2018)
Published in Cancer discovery (01.02.2018)
Get full text
Journal Article
Clinical Activity of Mitogen-Activated Protein Kinase-Targeted Therapies in Patients With Non-V600 BRAF-Mutant Tumors
Dankner, Matthew, Wang, Yifan, Fazelzad, Rouhi, Johnson, Benny, Nebhan, Caroline A, Dagogo-Jack, Ibiayi, Myall, Nathaniel J, Richtig, Georg, Bracht, Jillian W P, Gerlinger, Marco, Shinozaki, Eiji, Yoshino, Takayuki, Kotani, Daisuke, Fangusaro, Jason R, Gautschi, Oliver, Mazieres, Julien, Sosman, Jeffrey A, Kopetz, Scott, Subbiah, Vivek, Davies, Michael A, Groover, Anna L, Sullivan, Ryan J, Flaherty, Keith T, Johnson, Douglas B, Benedetti, Andrea, Cescon, David W, Spreafico, Anna, Zogopoulos, George, Rose, April A N
Published in JCO precision oncology (01.08.2022)
Published in JCO precision oncology (01.08.2022)
Get more information
Journal Article
Peripheral nervous system insulin resistance in ob/ob mice
Grote, Caleb W, Groover, Anna L, Ryals, Janelle M, Geiger, Paige C, Feldman, Eva L, Wright, Douglas E
Published in Acta neuropathologica communications (10.05.2013)
Published in Acta neuropathologica communications (10.05.2013)
Get full text
Journal Article
Targeting the MAPK Signaling Pathway in Cancer: Promising Preclinical Activity with the Novel Selective ERK1/2 Inhibitor BVD-523 (Ulixertinib)
Germann, Ursula A, Furey, Brinley F, Markland, William, Hoover, Russell R, Aronov, Alex M, Roix, Jeffrey J, Hale, Michael, Boucher, Diane M, Sorrell, David A, Martinez-Botella, Gabriel, Fitzgibbon, Matthew, Shapiro, Paul, Wick, Michael J, Samadani, Ramin, Meshaw, Kathryn, Groover, Anna, DeCrescenzo, Gary, Namchuk, Mark, Emery, Caroline M, Saha, Saurabh, Welsch, Dean J
Published in Molecular cancer therapeutics (01.11.2017)
Published in Molecular cancer therapeutics (01.11.2017)
Get full text
Journal Article
A phase 2 basket trial of ulixertinib (BVD-523) in combination with hydroxychloroquine in patients with advanced gastrointestinal malignancies harboring MAPK pathway mutations (BVD-523-HCQ)
Ko, Andrew H., Zalupski, Mark, Al-Rajabi, Raed Moh'd Taiseer, Matin, Khalid, Cohen, Deirdre Jill, Krishnamurthi, Smitha S., Kreider, Brent, Box, Jessica A., Emery, Caroline, Teresk, Martin, Varterasian, Mary Laura, Lee, Martin, Groover, Anna, Knoerzer, Deb, Shroff, Rachna T.
Published in Journal of clinical oncology (01.06.2023)
Published in Journal of clinical oncology (01.06.2023)
Get full text
Journal Article
Abstract 2692: The combination of ulixertinib (ERK1/2 Inhibitor) and KRASG12C inhibition demonstrates significant efficacy in preclinical models
Knoerzer, Deborah, Reddy, Anupama, Box, Jessica A., Groover, Anna, Kreider, Brent, Teresk, Martin, Emery, Caroline M.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
Abstract 2693: Combining ulixertinib (ERK1/2 Inhibitor) with EGFR and BRAF inhibition yields significant efficacy in preclinical BRAF V600E mutant colorectal cancer models
Knoerzer, Deborah, Reddy, Anupama, Box, Jessica A., Groover, Anna, Kreider, Brent, Teresk, Martin, Emery, Caroline M.
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Published in Cancer research (Chicago, Ill.) (04.04.2023)
Get full text
Journal Article
A two-part, phase II, multi-center study of the ERK inhibitor ulixertinib (BVD-523) for patients with advanced malignancies harboring MEK or atypical BRAF alterations (BVD-523-ABC)
Burkard, Mark E., McKean, Meredith, Rodon Ahnert, Jordi, Mettu, Niharika B., Jones, Jeremy Clifton, Misleh, Jamal Ghazi, Ma, Wen Wee, Lim, Kian-Huat, Chiorean, E. Gabriela, Pishvaian, Michael J., Gadgeel, Shirish M., McKean, Heidi Ann, Kreider, Brent, Knoerzer, Deb, Groover, Anna, Varterasian, Mary Laura, Box, Jessica A., Emery, Caroline, Sullivan, Ryan J.
Published in Journal of clinical oncology (01.06.2022)
Published in Journal of clinical oncology (01.06.2022)
Get full text
Journal Article